AbbVie Wins FDA Approval for New Migraine Indication
Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.
AbbVie Wins FDA Approval for New Migraine Indication Read More »
Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.
AbbVie Wins FDA Approval for New Migraine Indication Read More »
Desafiando una teoría paleoecológica muy aceptada desde hace tiempo, las conclusiones de un nuevo estudio indican que las hierbas que conforman la sabana existían en África oriental más de 10 millones de años antes de lo que se pensaba y las conclusiones de …
Los bosques herbáceos, más antiguos y con más influencia en la evolución humana Read More »
Los ordenadores y otros aparatos inteligentes que usamos en nuestra vida cotidiana necesitan de vez en cuando una actualización de su sistema operativo o de sus programas. Esto también le resulta útil a los robots ubicados fuera de la Tierra. Tras años de prepara …
Actualización de software para un robot que explora terrenos marcianos desde 2012 Read More »
El clima de la Tierra reproducido con una resolución sin precedentes en la supercomputadora más veloz del mundo Unos científicos han conseguido incorporar con éxito la actividad de las nubes en un modelo digital del clima de la Tierra, haciendo que alcance una re …
Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.
Vistagen today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C.
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share.
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities Read More »
Direct Biologics Reports Compelling Data as ExoFlo ™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects.
Nano Labs Ltd announced today that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2023.
Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2022 Read More »
MacuHealth, the leader in innovative eye supplements, is introducing LifeMeter, a portable, non-invasive device proven to measure the presence of vital antioxidants known as carotenoids.
MacuHealth Introduces LifeMeter to Measure Carotenoid Levels in Patients Read More »